A Randomised, Double-Blind, Placebo Controlled, Multi-Centre Phase II Study of Atacicept in Anti-TNF-alpha-naive Patients With Moderate to Severely Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate

Trial Profile

A Randomised, Double-Blind, Placebo Controlled, Multi-Centre Phase II Study of Atacicept in Anti-TNF-alpha-naive Patients With Moderate to Severely Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Feb 2016

At a glance

  • Drugs Atacicept (Primary) ; Adalimumab
  • Indications Rheumatoid arthritis
  • Focus Biomarker; Pharmacodynamics; Therapeutic Use
  • Acronyms AUGUST II
  • Sponsors EMD Serono
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 23 Jun 2012 Additiona trial location (Sweden) added as reported by European Clinical Trials Database.
    • 28 Apr 2012 Additional locations added as reported by European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top